Trial Search Results
Treatment of Schizoaffective Disorder Using Mifepristone
This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Collaborator: Pritzker Family Foundation
Stanford Investigator(s):
Intervention(s):
- Drug: Mifepristone
- Drug: Placebo Oral Tablet
Phase:
Phase 2/Phase 3
Eligibility
Inclusion Criteria:The subjects will be 30 inpatients or outpatients with schizoaffective
disorder. Exclusion Criteria:Subjects must be between the ages of eighteen and seventy-five
without major medical problems.
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jessica Hawkins
6507238323